We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioLineRx Announces Issuance of US Patent Covering Use of BL-8040 in Immunotherapy
News

BioLineRx Announces Issuance of US Patent Covering Use of BL-8040 in Immunotherapy

BioLineRx Announces Issuance of US Patent Covering Use of BL-8040 in Immunotherapy
News

BioLineRx Announces Issuance of US Patent Covering Use of BL-8040 in Immunotherapy

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioLineRx Announces Issuance of US Patent Covering Use of BL-8040 in Immunotherapy"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioLineRx Ltd. has announced that an Issue of Notification has been received from the United States Patent and Trademark Office (USPTO) for U.S. Patent No. 8,663,651, which includes claims to protect the use of BL-8040’s composition for enhancing immune responses to an antigen, such as a tumor-associated antigen.

The issued patent has a term extending to October 2029. This patent is part of BL-8040’s expanding patent portfolio, which includes 13 issued patents and 25 patent applications pending worldwide, providing a strong intellectual property estate around BL-8040.

“We are very pleased with this newly issued patent for BL-8040, which further strengthens the patent position we have for our leading oncology program. We view BL-8040 as a platform for multiple oncological and hematological indications, and robust patent protection provides us with the foundation to pursue these multiple indications for the BL-8040 platform,” stated Dr. Kinneret Savitsky, Chief Executive Officer of BioLineRx.

“BL-8040 is currently undergoing a Phase 2 trial for the treatment of acute myeloid leukemia and is expected to enter a Phase 1 trial for stem cell mobilization in the 2nd quarter of 2014. We expect top-line results for both of these clinical studies towards the end of the year or early next year,” concluded Dr. Savitsky.

Advertisement